Five commercial formulations of anti-leukemic drug (L-ASNase) are available for ALL treatment: three formulations are based on E. coli asparaginase (Elspar®; Leukanase; Kidrolase); a pegylated form of E. coli asparaginase (Oncaspar®); and recombinant asparaginase from Erwinia chrysanthemi (Erwinase®) [9]. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.